Pfizer's Abrysvo Hits Key Goals in Adults at Increased RSV Risk
By Colin Kellaher
Pfizer's Abrysvo vaccine for respiratory syncytial virus, or RSV, has met the key goals of a late-stage study in adults who are at increased risk of developing severe illness related to the virus.
Pfizer on Tuesday said the Phase 3 study evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age who are at risk of developing severe RSV-associated lower respiratory tract disease met its co-primary immunogenicity endpoints as well as its primary safety endpoint.
Pfizer said adults with certain underlying chronic conditions, such as asthma, diabetes and chronic obstructive pulmonary disease. are at increased risk of developing and being hospitalized for RSV-associated illness.
The U.S. Food and Drug Administration last year approved Abrysvo for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older and to help protect infants at birth through six months of life from lower respiratory tract disease due to RSV by active immunization of pregnant women.
New York drugmaker Pfizer on Tuesday said it plans to submit the new study data to regulatory agencies and to request expansion of the Abrysvo age group from the current indication to include adults 18 years of age and older.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 09, 2024 06:59 ET (10:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track